Please login to the form below

Not currently logged in
Email:
Password:

darolutamide

This page shows the latest darolutamide news and features for those working in and with pharma, biotech and healthcare.

Bayer bags FDA nod for early prostate cancer drug darolutamide

Bayer bags FDA nod for early prostate cancer drug darolutamide

Meanwhile, another phase 3 clinical trial called ARASENS is ongoing and is testing darolutamide in metastatic hormone-sensitive prostate cancer (HSPC) with results due in 2022. ... Bayer says it has also submitted darolutamide in the EU, Japan, and

Latest news

  • Bayer gains FDA priority review for prostate cancer drug Bayer gains FDA priority review for prostate cancer drug

    The move comes just two months after Bayer, and darolutamide-partner Orion, revealed positive late-stage data for the non-steroidal androgen receptor inhibitor. ... Darolutamide won’t have an easy time competing in against these products, however, as

  • Bayer, Orion prep challenge in prostate cancer market Bayer, Orion prep challenge in prostate cancer market

    New arrival will face tough competition, not least generic Zytiga. Bayer and Orion have put some meat on the bones of their phase 3 trial of darolutamide in non-metastatic ... The two partners released top-line results from the ARAMIS trial of

  • Bayer preps filings for new prostate cancer drug Bayer preps filings for new prostate cancer drug

    While there are already two rivals on the market, darolutamide’s developers think it has qualities which could make it a good option for patients. ... Under the terms of their 2014 agreement, Bayer has the right to commercialise darolutamide globally

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics